GDF-11 vs Humanin
A side-by-side research comparison of GDF-11 and Humanin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | GDF-11 | Humanin |
|---|---|---|
| Full name | Growth Differentiation Factor 11 | Humanin (HN) Mitochondrial-Derived Peptide |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Signals through activin type II receptors and SMAD2/3 to restore stem cell function, promote neurogenesis, and improve vascular remodeling in the context of aging. | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. |
| Molecular weight | 12,500 Da | 2,687 Da |
| Half-life | 6-8 hours | 4-6 hours |
| Bioavailability | Moderate (SubQ/IV) | Moderate (SubQ) |
| Typical dose | 0.1-0.5 mg/kg (research) | 1-5 mg |
| Frequency | Daily (animal studies) | 3-5x per week |
| Route | Subcutaneous | Subcutaneous |
GDF-11 reported benefits
- Potential tissue rejuvenation
- Neurogenesis stimulation
- Cardiac hypertrophy reversal
- Muscle stem cell activation
- Vascular remodeling
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Related comparisons
Research and educational reference only. Not medical advice.